Wong Yen Shen, Ibrahim Muhammad Amin, Mohd Zim Mohd Arif, Abdul Rani Mohd Fauzi
Faculty of Medicine, Universiti Teknologi MARA (UiTM), Sungai Buloh, Selangor, Malaysia.
Case Rep Med. 2022 Aug 4;2022:7512400. doi: 10.1155/2022/7512400. eCollection 2022.
Chronic respiratory disease may be associated with severity of coronavirus disease 2019 (COVID-19) infection. We review a case of chronic obstructive pulmonary disease (COPD) patient who developed acute breathlessness post COVID-19 infection, also focusing on the diagnostic approach.
A 69-year-old gentleman with background history of COPD GOLD D and ischemic heart disease was admitted with severe COVID-19 infection. He required high-flow nasal cannula upon presentation. A computed tomography pulmonary angiography (CTPA) thorax at day 10 of illness revealed moderate organizing pneumonia (OP) with emphysematous changes, without pulmonary embolism. He received oral baricitinib and intravenous methylprednisolone for 3 days, which was then followed by tapering prednisolone starting dose of 1 mg/kg/day (60 mg/day) with reduction of 10 mg prednisolone every 3 days. COPD pharmacotherapy was optimized with early utilization of dual bronchodilators and inhaled corticosteroid was withheld. He underwent inpatient pulmonary rehabilitation and was discharged with home oxygen therapy. Unfortunately, he was re-admitted after 2 weeks with shortness of breath and fever for 3 days. Blood results revealed leucocytosis with raised C-reactive protein. A repeat CTPA showed increase reticulations and crazy paving pattern with reduction in lung volume. Multidisciplinary team discussion concluded it as interstitial pneumonia with COVID-19 OP and fibrosis progression. Prednisolone was stopped and he responded well with antibiotics. A follow-up at 3 months post COVID-19 infection showed improvement of clinical symptoms with radiological resolution of ground glass changes.
Corticosteroid inhaler should be cautioned in this case, in view of recent pneumonia and non-elevated serum eosinophil count. These groups of patients should be closely followed up to unmask interstitial lung disease that may present prior to COVID-19 and worsen post-infection. Optimizing pre-existing medical conditions should be the paramount intervention.
慢性呼吸道疾病可能与2019冠状病毒病(COVID-19)感染的严重程度相关。我们回顾了1例慢性阻塞性肺疾病(COPD)患者,该患者在COVID-19感染后出现急性呼吸困难,并重点关注其诊断方法。
一名69岁男性,有COPD GOLD D级病史和缺血性心脏病史,因严重COVID-19感染入院。入院时需要高流量鼻导管吸氧。发病第10天的胸部计算机断层扫描肺动脉造影(CTPA)显示中度机化性肺炎(OP)伴肺气肿改变,无肺栓塞。他接受了3天的口服巴瑞替尼和静脉注射甲泼尼龙治疗,随后开始逐渐减量泼尼松龙,起始剂量为1mg/kg/天(60mg/天),每3天减少10mg泼尼松龙。早期使用双支气管扩张剂优化COPD药物治疗,停用吸入性糖皮质激素。他接受了住院肺康复治疗,并带着家庭氧疗出院。不幸的是,2周后他因气短和发热3天再次入院。血液检查结果显示白细胞增多,C反应蛋白升高。重复CTPA显示网状影增加和碎石路征,肺容积减小。多学科团队讨论认为这是伴有COVID-19 OP和纤维化进展的间质性肺炎。停用泼尼松龙,他对抗生素反应良好。COVID-19感染后3个月的随访显示临床症状改善,磨玻璃影在影像学上消退。
鉴于近期肺炎和血清嗜酸性粒细胞计数未升高,该病例应慎用糖皮质激素吸入剂。这些患者群体应密切随访,以发现可能在COVID-19之前出现并在感染后恶化的间质性肺病。优化既往存在的疾病应是首要干预措施。